Xanodyne files IPO registration with the SEC

NEWPORT, K.Y. Xanodyne Pharmaceuticals has filed a registration statement with the Securities and Exchange Commission to initiate public offering of its common stock.

Xanodyne produces products for pain management and women’s healthcare. The company manufactures prenatal vitamins like Duet DHA and Duet tablets and chewables. Some of Xanodynes’ pain drugs include, Darvocet-N 100, Hycet, and Roxicodone.

The number of shares to be offered and the price range for the proposed offering have not yet been determined. Xanodyne will sell all of the shares in the proposed offering.